Analyst Research

Report Title Price
Thomson Reuters Stock Report - CODEXIS, INCORPORATION (CDXS-O)
Provider: Thomson Reuters Stock Report
$25.00
Buy
Codexis, Inc. (CDXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Provider: GlobalData
$250.00
Buy
CODEXIS INC (CDXS) 12-months forecast
Provider: Pechala's Reports
$15.00
Buy
Codexis Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Codexis, Inc. Reaffirms FY 2012 Guidance


Thursday, 10 May 2012 04:01pm EDT 

Codexis, Inc. reaffirmed fiscal 2012 guidance and forecasts revenues in line with or exceeding fiscal 2011 results. The Company expects fiscal 2012 adjusted EBITDA to be positive. The Company reported revenues of $123.9 million in fiscal 2011. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $128 million for fiscal 2012. 

Latest Developments for Codexis Inc

Latest Key Developments in Biotechnology

Company Quote

Codexis Inc
(CDXS.O)
2.375
0.015 +0.64%
3:31pm EDT